Testing a new immune cell therapy for relapsed B-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial is testing a new treatment called CD19x22 CAR T cells for people with certain types of B-cell lymphoma that have come back or not responded to other treatments. The therapy uses your own immune cells, which are modified in a lab to better attack the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 16 years old (the first three people enrolled must be 18 or older).
- You must have a type of B-cell lymphoma that has not responded to at least two prior treatments, including specific drugs like anthracyclines and anti-CD20 antibodies.
- You must have measurable or evaluable disease—meaning the cancer can be seen on scans or other tests.
- You must have adequate organ function, including enough blood cells, healthy kidneys and liver, and good heart and lung function.
- You must not have active infections or serious medical conditions that would make the treatment unsafe.
- Women who can become pregnant must have a negative pregnancy test and agree to use birth control for 12 months after treatment; men must also agree to use birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called CD19 on your lymphoma cells. It's for people whose B-cell lymphoma has returned or not responded to standard treatments.
This trial tests a new combination treatment: first, natural killer cells (NK cells) that are engineered to find CD19, followed by CAR-T cells (also targeting CD19). It is for people with B-cell lymphoma that has come back or not responded to standard treatments.
This trial studies a type of lab-made immune cell therapy (CAR T) using cells called CAR-20/19-T. It is for adults with relapsed or refractory B-cell cancers, aiming to reduce or eliminate lymphoma in people whose disease has come back or not responded to standard treatments.
This trial tests a new type of CAR-T cell therapy for people with certain B-cell lymphomas that have come back or not responded to treatment. The CAR-T cells are made from a donor and are genetically edited to possibly work better and last longer.
This trial tests a new kind of immune cell therapy for people with certain types of lymphoma that have come back or not responded to previous treatments. The cells are made from your own blood and are designed to find and attack the cancer cells.
This trial tests a new type of CAR-T cell therapy designed to be stronger against B-cell lymphoma that has come back or not responded to previous treatments. The treatment uses your own immune cells, which are modified in a lab to better attack cancer cells.
Hear when a new Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.